Therapeutic Effect of Sodium Intake Reduction in Treatment Resistant Hypertension

Evaluation of the Therapeutic Effect of Sodium Intake Reduction by Education in Patients With Treatment Resistant Hypertension

The aim of this study was to evaluate the therapeutic effect of sodium intake reduction by education in patients with resistant hypertension.

The study was designed to maximize the compliance to antihypertensive agents and use optimal doses of antihypertensive agents including diuretics for 2 months before randomization. Patients will be assigned randomly to receiving (1) education of sodium intake reduction and exercise, or (2) education of exercise alone. Education of sodium intake reduction will be blinded to patients, and education of exercise will be provided to both group to blind the subjects. Daytime ambulatory blood pressure is adopted for diagnosis of resistant hypertension to avoid white-coat effect.

Study Overview

• Status: Terminated
• Conditions: Resistant Hypertension; Sodium Intake
• Intervention / Treatment: Behavioral: Sodium intake reduction; Behavioral: Exercise

Detailed Description

The study consists of 3 phases. The first phase is to exclude pseudo-resistant hypertension by improving compliance to antihypertensive medications. Patients should visit with a prescribed antihypertensive drugs to calculate compliance to medication. If patient has compliance to medication >= 85% [= (the number of pills dispensed - the number of pills counted) / the number of pills expected to have been taken (calculated by multiplying the daily dose by the number of days since the date dispensed)], ambulatory blood pressure will be measured.

If the patient had compliance to medication >= 85%, and daytime ambulatory blood pressure >=135/85 mmHg, he will be entered into first phase of treatment. If patient had compliance to medication <85%, patients will be asked to enhance medication adherence to 85% or more, and revisit after 1 months.

In the first phase of treatment, dose of current antihypertensive medications (diuretics should be included) will be escalated to optimal doses. Three or more classes of antihypertensive drugs should be prescribed, and educate to keep compliance to medication >=85%. The duration of second phase of treatment is 2 months. After start of first phase, there is a monitoring visit monitoring of adverse drug reaction of diuretics for safety. If there is adverse drug reaction, the dose of suspected drug will be decreased. After 2 months of treatment, if daytime ambulatory blood pressure is >= 135/85 mmHg with compliance to medication >=85%, the patients will be entered into second phase of treatment.

In the second phase of treatment, patients will be randomly assigned to receive either education of exercise or education of exercise and low sodium diet (intensive education with education materials). To the patients assigned to exercise education, detailed training of diet control using educational materials will not be provided. The patients will be blinded to educational group assignments. The duration of second phase of treatment is 1 month. Before start and after completion of second phase of treatment, the amount of sodium intake will be measured by 24-hour urine sodium excretion.

• Study Type: Interventional
• Enrollment (Actual): 5
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Korea, Republic of
  • Gyeonggi
    • Goyang, Gyeonggi, Korea, Republic of, 410-773
      • DongGuk University ilsan Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• individuals who agreed to participate in the study and submitted written informed consent
• individuals aged 20 or more years
• Hypertensive patients whose blood pressure is not controlled normally while taking three or more antihypertensive agents including diuretics
• Diuretics should be Hydrochlorothiazide or Indapamide

Exclusion Criteria:

• Systolic blood pressure ≥ 220 mmHg
• Chronic kidney disease: estimated Glomerular filtration rate by Modification of Diet in Renal Disease formula ≤ 30 mL/min
• Hyperkalemia (>5.5 mmol/L) or hypokalemia (<3.5 mmol/L)
• Hyponatremia (<135 mmol/L)
• Major cardiovascular events (MI, unstable angina, coronary revascularization, stroke) within 6 month of screening
• Retinal bleeding within 3 months
• Heart failure stage 3 or 4
• Severe liver disease
• Pregnancy or women in the fertile age not using efficient contraceptive methods
• Alcoholism
• Renovascular disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Sodium intake reduction and exercise; education of sodium intake reduction and regular exercise	Behavioral: Sodium intake reduction; Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively; Behavioral: Exercise; Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
Placebo Comparator: Exercise; education of regular exercise only	Behavioral: Exercise; Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference of change of sitting systolic blood pressure	Comparison of the difference of sitting systolic blood pressure after completion of second phase of treatment (sodium intake reduction phase) from randomization of Second phase of treatment between groups	from randomization to completion of second phase of treatment (sodium intake reduction phase, for 1 month)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of optimized antihypertensive treatment	Percent of responders (sitting SBP < 90 mmHg or difference of sitting SBP > 10 mmHg from randomization) at the end of first phase treatment	At the end of First phase of treatment (for 2 months)
Effect of optimized antihypertensive treatment	Comparison of changes of systolic and diastolic blood pressure lowering at the end of the First phase of treatment from baseline	From the start to the end of First phase of treatment (for 2 months)
Effect of sodium intake reduction	Difference of change of sitting diastolic blood pressure between groups (exercise vs exercise + sodium intake reduction) after completion of the Second phase of treatment (sodium intake reduction phase) from randomization of Second phase of treatment	from randomization to completion of second phase of treatment (sodium intake reduction phase, for 1 month)
Comparison of Percent of responders at the end of first phase treatment between groups	Comparison of percent responders between groups (sitting SBP < 90 mmHg or difference of sitting SBP > 10 mmHg from randomization) at the end of second phase of treatment	at the end of second phase of treatment (sodium intake reduction phase, for 1 month)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference of renin and aldosterone level between non-resistant hypertension vs resistant hypertension	Comparison of renin and aldosterone level between non-resistant hypertension vs resistant hypertension after optimized antihypertensive treatment	after completion of first phase treatment (2 months)
Difference of the effect of sodium intake reduction on renin and aldosterone level between responders vs non-responders to sodium intake reduction	Comparison of renin and aldosterone level between responders vs non-responders to sodium intake reduction	after completion of second phase treatment (1 month)
Effect of compliance improvement in BP control	Effect of compliance improvement in BP control	Phase of improving drug adherence (1 month)

Collaborators and Investigators

• Sponsor: DongGuk University
• Investigators: Principal Investigator: Moo-Yong Rhee, MD, Dongguk University Ilsan Hospital/Cardiovascular Center

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2018
• Primary Completion (Actual): January 31, 2020
• Study Completion (Actual): August 31, 2020

Study Registration Dates

• First Submitted: November 16, 2017
• First Submitted That Met QC Criteria: January 31, 2018
• First Posted (Actual): February 7, 2018

Study Record Updates

• Last Update Posted (Actual): July 12, 2021
• Last Update Submitted That Met QC Criteria: July 7, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Hypertension
• Other Study ID Numbers: DUMC-C1701

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: The study data will be shared with investigators who will participate this study as primary investigator or sub-investigator.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No